Oliver Wirths

List of Publications by Year in Descending Order

112 papers	5,516 citations	42 h-index	72 g-index
131 ext. papers	6,195 ext. citations	6 avg, IF	5.69 L-index

#	Paper	IF	Citations
112	Detection and Quantification of Aβ-40 (APP669-711) in Cerebrospinal Fluid.. *Journal of Neurochemistry*, **2022**,	6	1
111	An inhibitory effect on the nuclear accumulation of phospho-STAT1 by its unphosphorylated form.. *Cell Communication and Signaling*, **2022**, 20, 42	7.5	
110	Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer's disease.. *Cellular and Molecular Life Sciences*, **2022**, 79, 168	10.3	0
109	Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy. *Nature Communications*, **2021**, 12, 6530	17.4	1
108	A microRNA signature that correlates with cognition and is a target against cognitive decline. *EMBO Molecular Medicine*, **2021**, 13, e13659	12	3
107	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2021**, 13, 94	9	2
106	Characterization of a Mouse Model of Alzheimer's Disease Expressing Aβ42-42 and Human Mutant Tau. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
105	Physical activity and cognitive stimulation ameliorate learning and motor deficits in a transgenic mouse model of Alzheimer's disease. *Behavioural Brain Research*, **2021**, 397, 112951	3.4	2
104	Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease. *Molecular Neurobiology*, **2021**, 58, 204-216	6.2	11
103	The anti-parallel dimer binding interface in STAT3 transcription factor is required for the inactivation of cytokine-mediated signal transduction. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2021**, 1868, 119118	4.9	0
102	Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis.. *Cellular and Molecular Life Sciences*, **2021**, 79, 1	10.3	4
101	N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2020**, 46, 673-685	5.2	12
100	Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer's Disease. *ASN Neuro*, **2020**, 12, 1759091420925356	5.3	6
99	Neuron Loss in Alzheimer's Disease: Translation in Transgenic Mouse Models. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
98	Development and Technical Validation of an Immunoassay for the Detection of APP (Aβ in Biological Samples. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
97	N-Terminal Truncated Aβ4-42 Is a Substrate for Neprilysin Degradation in vitro and in vivo. *Journal of Alzheimer's Disease*, **2019**, 67, 849-858	4.3	10
96	Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer's Disease. *ASN Neuro*, **2019**, 11, 1759091419892692	5.3	7

95	Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer's disease. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 991-1004	6.4	24
94	The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. *Acta Neuropathologica*, **2019**, 137, 239-257	14.3	24
93	Synergistic Effect on Neurodegeneration by N-Truncated Aβ and Pyroglutamate Aβ in a Mouse Model of Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2018**, 10, 64	5.3	10
92	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. *Acta Neuropathologica Communications*, **2018**, 6, 62	7.3	3
91	A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 121	9	25
90	Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. *Acta Neuropathologica Communications*, **2018**, 6, 108	7.3	44
89	Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease. *Molecular Neurobiology*, **2017**, 54, 319-327	6.2	11
88	N-truncated Aβ peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. *Alzheimer's Research and Therapy*, **2017**, 9, 80	9	26
87	Altered neurogenesis in mouse models of Alzheimer disease. *Neurogenesis (Austin, Tex)*, **2017**, 4, e1327002		31
86	Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice. *Molecular Neurobiology*, **2017**, 54, 6542-6555	6.2	30
85	Extraction of Soluble and Insoluble Protein Fractions from Mouse Brains and Spinal Cords. *Bio-protocol*, **2017**, 7, e2422	0.9	2
84	Preparation of Crude Synaptosomal Fractions from Mouse Brains and Spinal Cords. *Bio-protocol*, **2017**, 7, e2423	0.9	8
83	Immunotherapy Against N-Truncated Amyloid-β Oligomers. *Methods in Pharmacology and Toxicology*, **2016**, 37-50	1.1	3
82	Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model. *Translational Psychiatry*, **2016**, 6, e800	8.6	48
81	Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 50, 397-409	4.3	7
80	N-truncated Aβ-X starting with position two in sporadic Alzheimer's disease cases and two Alzheimer mouse models. *Journal of Alzheimer's Disease*, **2016**, 49, 101-10	4.3	8
79	Effects of Long-Term Environmental Enrichment on Anxiety, Memory, Hippocampal Plasticity and Overall Brain Gene Expression in C57BL6 Mice. *Frontiers in Molecular Neuroscience*, **2016**, 9, 62	6.1	52
78	Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models. *Acta Neuropathologica Communications*, **2016**, 4, 24	7.3	22

77	Phosphorylation of the amyloid peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. *Acta Neuropathologica*, **2016**, 131, 525-37	14.3	65
76	The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination. *CNS Neuroscience and Therapeutics*, **2016**, 22, 387-95	6.8	21
75	Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. *Journal of Alzheimers Disease*, **2015**, 45, 1223-36	4.3	38
74	Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. *Journal of Alzheimers Disease*, **2015**, 44, 1291-302	4.3	45
73	I716F APP mutation associates with the deposition of oligomeric pyroglutamate amyloid- and synucleinopathy with Lewy bodies. *Journal of Alzheimers Disease*, **2015**, 44, 103-14	4.3	9
72	Immunocytochemical Detection of Intraneuronal A Peptides in Mouse Models of Alzheimers Disease. *Neuromethods*, **2015**, 179-193	0.4	
71	Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. *Acta Neuropathologica*, **2014**, 127, 787-801	14.3	99
70	Abundance of Ak like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. *Molecular Neurodegeneration*, **2014**, 9, 13	19	18
69	Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. *Frontiers in Aging Neuroscience*, **2014**, 6, 75	5.3	57
68	Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal A accumulation. *Frontiers in Aging Neuroscience*, **2014**, 6, 139	5.3	21
67	A38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. *Journal of Alzheimers Disease*, **2014**, 39, 871-81	4.3	19
66	Immunolesion-induced loss of cholinergic projection neurones promotes amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice. *Neuropathology and Applied Neurobiology*, **2014**, 40, 106-20	5.2	25
65	N-truncated amyloid (A)4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. *Acta Neuropathologica*, **2013**, 126, 189-205	14.3	123
64	Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. *Acta Neuropathologica*, **2013**, 125, 699-709	14.3	60
63	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. *Acta Neuropathologica Communications*, **2013**, 1, 56	7.3	31
62	Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2564-73	5.6	45
61	Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias. *Neurobiology of Aging*, **2013**, 34, 1416-25	5.6	12
60	Problems During Aging (Alzheimers and Others) **2013**, 2953-2969		

59	The Arctic APP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A. *Acta Neuropathologica Communications*, **2013**, 1, 60	7.3	27
58	Oligomeric pyroglutamate amyloid- is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy. *Journal of Alzheimer's Disease*, **2013**, 35, 741-9	4.3	14
57	Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. *Neurobiology of Aging*, **2012**, 33, 96-107	5.6	63
56	Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A aggregation in the 5XFAD mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 196.e29-40	5.6	281
55	No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 833.e39-50	5.6	29
54	Amyloid precursor protein is a biomarker for transformed human pluripotent stem cells. *American Journal of Pathology*, **2012**, 180, 1636-52	5.8	11
53	Intraneuronal A accumulation and neurodegeneration: lessons from transgenic models. *Life Sciences*, **2012**, 91, 1148-52	6.8	65
52	Pyroglutamate amyloid (A) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. *Journal of Biological Chemistry*, **2012**, 287, 8154-62	5.4	60
51	APP accumulation and/or intraneuronal amyloid- accumulation? The 3xTg-AD mouse model revisited. *Journal of Alzheimer's Disease*, **2012**, 28, 897-904	4.3	27
50	Antibody 9D5 recognizes oligomeric pyroglutamate amyloid- in a fraction of amyloid- deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. *Journal of Alzheimer's Disease*, **2012**, 29, 361-71	4.3	15
49	Reduced levels of IgM autoantibodies against N-truncated pyroglutamate A in plasma of patients with Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 1379-87	5.6	21
48	Intraneuronal A as a trigger for neuron loss: can this be translated into human pathology?. *Biochemical Society Transactions*, **2011**, 39, 857-61	5.1	23
47	Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. *Journal of Biological Chemistry*, **2011**, 286, 4454-60	5.4	64
46	Pyroglutamate amyloid-(A) a hatchet man in Alzheimer disease. *Journal of Biological Chemistry*, **2011**, 286, 38825-32	5.4	146
45	Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. *Frontiers in Aging Neuroscience*, **2010**, 2, 8	5.3	126
44	Neuron loss in transgenic mouse models of Alzheimer's disease. *International Journal of Alzheimer's Disease*, **2010**, 2010,	3.7	49
43	Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. *Journal of Biological Chemistry*, **2010**, 285, 41517-24	5.4	75
42	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. *World Journal of Biological Psychiatry*, **2010**, 11, 243-50	3.8	37

41	Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. *Journal of Biological Chemistry*, **2010**, 285, 10678-89	5.4	94
40	Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. *Journal of Chemical Neuroanatomy*, **2010**, 40, 82-92	3.2	25
39	Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2010**, 31, 747-57	5.6	85
38	Intracellular A triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2010**, 31, 1153-63	5.6	56
37	Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. *Acta Neuropathologica*, **2010**, 119, 555-66	14.3	72
36	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. *Journal of Neural Transmission*, **2010**, 117, 85-96	4.3	80
35	Formic acid is essential for immunohistochemical detection of aggregated intraneuronal Abeta peptides in mouse models of Alzheimer's disease. *Brain Research*, **2009**, 1301, 116-25	3.7	29
34	Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease. *Journal of Neural Transmission*, **2009**, 116, 913-20	4.3	19
33	APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. *Acta Neuropathologica*, **2009**, 117, 677-85	14.3	67
32	Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. *Acta Neuropathologica*, **2009**, 118, 487-96	14.3	132
31	Die modifizierte Amyloid-Hypothese der Alzheimer-Demenz Intraneuronales Abeta induziert Neurodegeneration. *E-Neuroforum*, **2009**, 15, 76-83		
30	Age-dependent loss of dentate gyrus granule cells in APP/PS1KI mice. *Brain Research*, **2008**, 1222, 207-13	3.7	18
29	Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 891-901	5.6	64
28	Intraneuronal beta-amyloid is a major risk factor--novel evidence from the APP/PS1KI mouse model. *Neurodegenerative Diseases*, **2008**, 5, 140-2	2.3	13
27	Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *Journal of Neural Transmission*, **2008**, 115, 1651-9	4.3	42
26	Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. *Acta Neuropathologica*, **2008**, 116, 647-55	14.3	98
25	Review on the APP/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. *Genes, Brain and Behavior*, **2008**, 7 Suppl 1, 6-11	3.6	39
24	Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models. *Genes, Brain and Behavior*, **2008**, 7 Suppl 1, 1-5	3.6	51

23	Early Intraneuronal Amyloid Pathology: Do Transgenic Mice Represent Valid Model Systems? **2008**, 2, 7-12		2
22	Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. *Brain Research*, **2007**, 1152, 209-14	3.7	6
21	Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. *Journal of Neural Transmission*, **2007**, 114, 387-94	4.3	40
20	Age-dependent axonal degeneration in an Alzheimer mouse model. *Neurobiology of Aging*, **2007**, 28, 1689-99	5.6	91
19	Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. *Experimental Gerontology*, **2006**, 41, 220-4	4.5	16
18	OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 176-86	3.1	57
17	Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. *Acta Neuropathologica*, **2006**, 111, 312-9	14.3	94
16	Traumatic brain injury: cause or risk of Alzheimer's disease? A review of experimental studies. *Journal of Neural Transmission*, **2005**, 112, 1547-64	4.3	56
15	A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. *Journal of Neurochemistry*, **2004**, 91, 513-20	6	304
14	Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. *American Journal of Pathology*, **2004**, 164, 1495-502	5.8	212
13	Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. *American Journal of Pathology*, **2004**, 165, 1289-300	5.8	338
12	Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. *Laboratory Investigation*, **2003**, 83, 429-34	5.9	122
11	Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. *Experimental Neurology*, **2003**, 184, 247-63	5.7	225
10	Alpha-synuclein, Abeta and Alzheimer's disease. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2003**, 27, 103-8	5.5	32
9	No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. *Neurobiology of Disease*, **2003**, 12, 110-20	7.5	37
8	Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. *Brain Pathology*, **2002**, 12, 275-86	6	104
7	Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. *Brain Pathology*, **2001**, 11, 1-11	6	136
6	Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. *Neuroscience Letters*, **2001**, 306, 116-20	3.3	285

5	Reelin in plaques of beta-amyloid precursor protein and presenilin-1 double-transgenic mice. *Neuroscience Letters*, **2001**, 316, 145-8	3.3	50
4	Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. *NeuroReport*, **2000**, 11, 3737-41	1.7	42
3	N-Terminally Truncated A Peptide Variants in Alzheimer Disease107-122		2
2	Immunotherapy Targeting Amyloid- Peptides in Alzheimer Disease23-49		1
1	Ageing-associated myelin dysfunction drives amyloid deposition in mouse models of Alzheimer disease		3